Published in Cancer Res on December 01, 1995
The L6 membrane proteins--a new four-transmembrane superfamily. Protein Sci (2000) 1.24
TM4SF1: a new vascular therapeutic target in cancer. Angiogenesis (2014) 0.90
TM4SF1 Promotes Gemcitabine Resistance of Pancreatic Cancer In Vitro and In Vivo. PLoS One (2015) 0.78
Prediction of myelotoxicity using semi-quantitative marrow image scores. J Nucl Med (1997) 1.94
Radioassay of yttrium-90 radiation using the radionuclide dose calibrator. J Nucl Med (1997) 1.68
Clinical assessment of left ventricular regional contraction patterns and ejection fraction by high-resolution gated scintigraphy. J Nucl Med (1975) 1.48
The ventilatory lung scan in the diagnosis of pulmonary embolism. N Engl J Med (1970) 1.44
131I-Lym-1 in mice implanted with human Burkitt's lymphoma (Raji) tumors: loss of tumor specificity due to radiolysis. Cancer Biother Radiopharm (2000) 1.39
Copper chelates as probes of biological systems: stable copper complexes with a macrocyclic bifunctional chelating agent. Anal Biochem (1985) 1.33
Copper-67-labeled monoclonal antibody Lym-1, a potential radiopharmaceutical for cancer therapy: labeling and biodistribution in RAJI tumored mice. J Nucl Med (1988) 1.17
Planar gamma camera imaging and quantitation of yttrium-90 bremsstrahlung. J Nucl Med (1994) 1.15
NanoFerrite particle based radioimmunonanoparticles: binding affinity and in vivo pharmacokinetics. Bioconjug Chem (2008) 1.11
Increased survival associated with radiolabeled Lym-1 therapy for non-Hodgkin's lymphoma and chronic lymphocytic leukemia. Cancer (1997) 1.11
A comparative study of copper-67 radiolabeling and kinetic stabilities of antibody-macrocycle chelate conjugates. Cancer (1994) 1.09
Potential use of amino acid cocktails to reduce renal tubular reabsorption of radioconjugates. J Nucl Med (1996) 1.08
Maximum-tolerated dose, toxicity, and efficacy of (131)I-Lym-1 antibody for fractionated radioimmunotherapy of non-Hodgkin's lymphoma. J Clin Oncol (1998) 1.07
Pre-clinical evaluation and efficacy studies of a melanin-binding IgM antibody labeled with 188Re against experimental human metastatic melanoma in nude mice. Cancer Biol Ther (2008) 1.07
Effect of the extent of chelate substitution on the immunoreactivity and biodistribution of 2IT-BAT-Lym-1 immunoconjugates. Cancer Res (1995) 1.06
Synergy of Taxol and radioimmunotherapy with yttrium-90-labeled chimeric L6 antibody: efficacy and toxicity in breast cancer xenografts. Proc Natl Acad Sci U S A (1997) 1.04
Scintigraphy in the diagnosis of osteonecrosis. Clin Orthop Relat Res (1978) 1.02
Review of a 5-year experience with the radiostrontium bone scintiscan. Calif Med (1972) 1.02
Direct dose confirmation of quantitative autoradiography with micro-TLD measurements for radioimmunotherapy. J Nucl Med (1988) 1.01
Apoptosis-related gene and protein expression in human lymphoma xenografts (Raji) after low dose rate radiation using 67Cu-2IT-BAT-Lym-1 radioimmunotherapy. Cancer Biother Radiopharm (2001) 1.01
Serum stability of 67Cu chelates: comparison with 111In and 57Co. Int J Rad Appl Instrum B (1986) 1.00
Transfer of copper from a chelated 67Cu-antibody conjugate to ceruloplasmin in lymphoma patients. Nucl Med Biol (1999) 0.99
Yttrium-90-labeled monoclonal antibody for therapy: labeling by a new macrocyclic bifunctional chelating agent. J Nucl Med (1990) 0.97
Low-dose, fractionated radioimmunotherapy for B-cell malignancies using 131I-Lym-1 antibody. Cancer Biother Radiopharm (1998) 0.96
Assessment of conventional criteria for the early diagnosis of thrombophlebitis with the 125I-fibrinogen uptake test. Radiology (1977) 0.96
Radioimmunotherapy: recent results and future directions. J Clin Oncol (1996) 0.96
Scintigraphic imaging of a blind-ending ureteral duplication. J Nucl Med (1975) 0.96
67Cu-versus 131I-labeled Lym-1 antibody: comparative pharmacokinetics and dosimetry in patients with non-Hodgkin's lymphoma. Clin Cancer Res (1999) 0.94
Comparative serum stability of radiochelates for antibody radiopharmaceuticals. J Nucl Med (1987) 0.94
Systemic radiotherapy in metastatic breast cancer using 90Y-linked monoclonal MUC-1 antibodies. Crit Rev Oncol Hematol (2001) 0.94
Blood flow in irradiated mouse sarcoma as determined by the clearance of xenon-133. Cancer Res (1972) 0.94
Vascularity of the femoral head. Tc diphosphonate scintigraphy validated with tetracycline labeling. Clin Orthop Relat Res (1977) 0.94
Technetium-99m NGA functional hepatic imaging: preliminary clinical experience. J Nucl Med (1985) 0.94
Macrocyclic chelates of radiometals for diagnosis and therapy. Br J Cancer Suppl (1990) 0.93
Factors affecting 131I-Lym-1 pharmacokinetics and radiation dosimetry in patients with non-Hodgkin's lymphoma and chronic lymphocytic leukemia. J Nucl Med (1999) 0.93
85 Sr bone scan in neoplastic disease. Semin Nucl Med (1972) 0.93
Stable bifunctional chelates of metals used in radiotherapy. Cancer Res (1990) 0.93
Comparative toxicity studies of yttrium-90 MX-DTPA and 2-IT-BAD conjugated monoclonal antibody (BrE-3). Cancer (1994) 0.92
Quantitative bremsstrahlung imaging of yttrium-90 using a Wiener filter. Med Phys (1994) 0.92
Radionuclide assessment of nitroglycerin influence on abnormal left ventricular segmental contraction in patients with coronary heart disease. Circulation (1976) 0.91
The 85-Sr scintiscan in bone disease. Ann Intern Med (1966) 0.91
Practical determination of patient-specific marrow dose using radioactivity concentration in blood and body. J Nucl Med (1999) 0.90
A clinical trial of radioimmunotherapy with 67Cu-2IT-BAT-Lym-1 for non-Hodgkin's lymphoma. J Nucl Med (1999) 0.90
Quantitative imaging of mouse L-6 monoclonal antibody in breast cancer patients to develop a therapeutic strategy. Int J Rad Appl Instrum B (1991) 0.90
Antiangiogenic agents and their promising potential in combined therapy. Crit Rev Oncol Hematol (2001) 0.90
A radioimmunoimaging and MIRD dosimetry treatment planning program for radioimmunotherapy. Nucl Med Biol (1996) 0.89
Sodium flux in myotonic muscular dystrophy. Am J Physiol (1968) 0.88
Anti-HLA-DR/anti-DOTA diabody construction in a modular gene design platform: bispecific antibodies for pretargeted radioimmunotherapy. Cancer Biother Radiopharm (2001) 0.88
Hepatic scintiangiographic patterns. Radiology (1974) 0.88
Treatment of B cell malignancies with 131I Lym-1 monoclonal antibodies. Int J Cancer Suppl (1988) 0.87
Growth and differentiation of transplanted W/Wv marrow. Blood (1967) 0.87
Role of radiation dosimetry in radioimmunotherapy planning and treatment dosing. Crit Rev Oncol Hematol (2001) 0.87
Critical evaluation of hepatic scintiangiography for neoplastic tumors of the liver. J Nucl Med (1975) 0.87
New approach to interpretation of technetium-99m pyrophosphate scintigraphy in detection of acute myocardial infarction: clinical assessment of diagnostic accuracy. Am J Cardiol (1977) 0.87
Origin and evolution of radioactive pulmonary emboli in man. Radiology (1968) 0.86
L6 monoclonal antibody binds prostate cancer. Prostate (1998) 0.85
Neovascular targeting with cyclic RGD peptide (cRGDf-ACHA) to enhance delivery of radioimmunotherapy. Cancer Biother Radiopharm (2000) 0.85
Labeling monoclonal antibodies with 90yttrium- and 111indium-DOTA chelates: a simple and efficient method. Bioconjug Chem (1994) 0.84
The biologic window for chimeric L6 radioimmunotherapy. Cancer (1994) 0.84
Detection of bone lesions with the strontium-85 scintiscan. J Nucl Med (1966) 0.84
Scintiscanning in malignant lymphomatous involvement of bone. Arch Intern Med (1968) 0.84
Efficacy and toxicity of 67Cu-2IT-BAT-Lym-1 radioimmunoconjugate in mice implanted with human Burkitt's lymphoma (Raji). Clin Cancer Res (1997) 0.83
Treatment of a patient with B cell lymphoma by I-131 LYM-1 monoclonal antibodies. Int J Biol Markers (1988) 0.83
Prediction of radiation doses from therapy using tracer studies with iodine-131-labeled antibodies. J Nucl Med (1996) 0.83
Optimized conditions for chelation of yttrium-90-DOTA immunoconjugates. J Nucl Med (1998) 0.83
Fractionated radioimmunotherapy of B-cell malignancies with 131I-Lym-1. Cancer Res (1990) 0.83
Trials and tribulations: oncological antibody imaging comes to the fore. Semin Nucl Med (1997) 0.83
Evaluation of the liver and spleen in Hodgkin's disease. I. The value of hepatic scintigraphy. Am J Med (1972) 0.82
Radioimmunotherapy with (111)In/(90)Y-2IT-BAD-m170 for metastatic prostate cancer. Clin Cancer Res (2001) 0.82